Suppr超能文献

司帕沙星与环丙沙星治疗复杂性尿路感染的疗效比较

Comparative efficacy of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection.

作者信息

Naber K G, di Silverio F, Geddes A, Guibert J

机构信息

Urologic Clinic, Elisabeth Hospital, Straubing, Germany.

出版信息

J Antimicrob Chemother. 1996 May;37 Suppl A:135-44. doi: 10.1093/jac/37.suppl_a.135.

Abstract

A total of 686 adult patients with complicated urinary tract infections were enrolled in a double-blind, randomised, multicentre study to compare sparfloxacin (200 mg loading dose on day 1 followed by 100 mg daily) with ciprofloxacin (500 mg orally twice daily) for 10 to 14 days. Urinary tract infection was defined as pyuria and bacteriuria (cfu > or = 10(5)/mL). Evaluations were performed at four time-points. The clinical efficacy of the two antibacterial agents was equivalent at the end of treatment: clinical cure in 88.6% of the intent-to-treat population and 87.3% in the evaluable population treated with sparfloxacin compared to 85.4% and 84.8% of the intent-to-treat and evaluable populations, respectively, treated with ciprofloxacin. The clinical results were also equivalent at follow-up. The bacteriological efficacy of the two agents was not equivalent. At the end of treatment, bacteriological cure was observed in 72.6% of the intent-to-treat and 72.1% of the evaluable populations treated with sparfloxacin and in 81.4% and 80.8% of the intent-to-treat and evaluable populations, respectively, treated with ciprofloxacin. The difference was primarily because of a higher number of persisting pathogens, which included Enterobacteriaceae other than Escherichia coli, Pseudomonas aeruginosa and enterococci, which exhibited moderate susceptibility to sparfloxacin. Tolerability was similar in the two treatment groups.

摘要

共有686例患有复杂性尿路感染的成年患者参加了一项双盲、随机、多中心研究,以比较司帕沙星(第1天给予200mg负荷剂量,随后每日100mg)与环丙沙星(每日口服500mg,分两次)治疗10至14天的效果。尿路感染定义为脓尿和菌尿(菌落形成单位>或=10⁵/mL)。在四个时间点进行评估。两种抗菌药物在治疗结束时临床疗效相当:在意向性治疗人群中,司帕沙星治疗组的临床治愈率为88.6%,可评估人群中为87.3%;相比之下,环丙沙星治疗组在意向性治疗人群和可评估人群中的临床治愈率分别为85.4%和84.8%。随访时临床结果也相当。两种药物的细菌学疗效不相当。治疗结束时,司帕沙星治疗的意向性治疗人群和可评估人群中细菌学治愈率分别为72.6%和72.1%,环丙沙星治疗的意向性治疗人群和可评估人群中分别为81.4%和80.8%。差异主要是由于持续存在的病原体数量较多,其中包括除大肠杆菌外的肠杆菌科细菌、铜绿假单胞菌和肠球菌,这些病原体对司帕沙星表现出中度敏感性。两个治疗组的耐受性相似。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验